Accès ouvert
2023
other
OpenAlex
Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H. M. van Deurzen et autres
Figure S1: Schematic workflow of RAD51IRIF assay and accessory experimental timeline. Figure S2: Validation of RAD51 IRIF immunostaining: 2 hours post IR is optimal for RAD51 focus formation which are only formed in GEMININ positive cells Figure S3: ᵞ-H2AX and 53BP1 nuclear …
Accès ouvert
2023
other
OpenAlex
Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H. M. van Deurzen et autres
Figure S1: Schematic workflow of RAD51IRIF assay and accessory experimental timeline. Figure S2: Validation of RAD51 IRIF immunostaining: 2 hours post IR is optimal for RAD51 focus formation which are only formed in GEMININ positive cells Figure S3: ᵞ-H2AX and 53BP1 nuclear …
Accès ouvert
2023
supplementary-materials
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
Table S3 gives an overview of the detected class 3, 4 and 5 variants in the final cohort.
Accès ouvert
2023
supplementary-materials
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
Supplementary Material and Methods
Accès ouvert
2023
supplementary-materials
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
Figure S2 shows that their is an unbiased natural devision between samples analyes by the oncoscan platform and the CGH Agilent platform.
Accès ouvert
2023
supplementary-materials
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
Table S2 shows the clinicopathological characteristics of the homologous recombination intermediate cases.
Accès ouvert
2023
supplementary-materials
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
Table S1 shows the clinicopathological characteristics of the cases included in final analysis.
Accès ouvert
2023
other
OpenAlex
Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H. M. van Deurzen et autres
Abstract Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors are promising targeted treatment options for hereditary breast tumors with a homologous recombination (HR) deficiency caused by BRCA1 or BRCA2 mutations. However, the functional consequence of BRCA gene mutations is not always known and tumors can …
Accès ouvert
2023
other
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
AbstractPurpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers and its association …
Accès ouvert
2023
other
OpenAlex
Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H. M. van Deurzen et autres
Abstract Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors are promising targeted treatment options for hereditary breast tumors with a homologous recombination (HR) deficiency caused by BRCA1 or BRCA2 mutations. However, the functional consequence of BRCA gene mutations is not always known and tumors can …
Accès ouvert
2023
other
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
AbstractPurpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers and its association …
Accès ouvert
2023
supplementary-materials
OpenAlex
Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres
Figure S1 shows that the Oncoscan and CGH agilent platform yield similar results.